- Home
- IONS vs BDC Comparison
IONS vs BDC Comparison
Compare IONS & BDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- BDC
- Stock Information
- Founded
- IONS 1989
- BDC 1902
- Country
- IONS United States
- BDC United States
- Employees
- IONS N/A
- BDC N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- BDC Telecommunications Equipment
- Sector
- IONS Health Care
- BDC Telecommunications
- Exchange
- IONS Nasdaq
- BDC Nasdaq
- Market Cap
- IONS 4.6B
- BDC 4.1B
- IPO Year
- IONS 1991
- BDC 1993
- Fundamental
- Price
- IONS $28.40
- BDC $94.02
- Analyst Decision
- IONS Buy
- BDC Strong Buy
- Analyst Count
- IONS 18
- BDC 6
- Target Price
- IONS $57.00
- BDC $128.50
- AVG Volume (30 Days)
- IONS 2.0M
- BDC 355.5K
- Earning Date
- IONS 04-30-2025
- BDC 05-01-2025
- Dividend Yield
- IONS N/A
- BDC 0.21%
- EPS Growth
- IONS N/A
- BDC N/A
- EPS
- IONS N/A
- BDC 4.80
- Revenue
- IONS $705,138,000.00
- BDC $2,460,979,000.00
- Revenue This Year
- IONS N/A
- BDC $9.27
- Revenue Next Year
- IONS $25.80
- BDC $5.32
- P/E Ratio
- IONS N/A
- BDC $19.59
- Revenue Growth
- IONS N/A
- BDC N/A
- 52 Week Low
- IONS $23.95
- BDC $80.90
- 52 Week High
- IONS $52.34
- BDC $131.82
- Technical
- Relative Strength Index (RSI)
- IONS 44.54
- BDC 43.42
- Support Level
- IONS $27.57
- BDC $91.59
- Resistance Level
- IONS $29.04
- BDC $96.50
- Average True Range (ATR)
- IONS 1.79
- BDC 5.47
- MACD
- IONS 0.12
- BDC 0.21
- Stochastic Oscillator
- IONS 68.15
- BDC 49.88
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About BDC Belden Inc
Belden Inc provides signal transmission products to distributors, end-users, installers, and original equipment manufacturers. The firm operates in two segments - Smart Infrastructure Solutions and Automation Solutions. Smart Infrastructure Solutions segment is a provider in network infrastructure and broadband solutions, as well as cabling and connectivity solutions for commercial audio/video and security applications. Automation Solutions segment provides network infrastructure and digitization solutions to enable customers to make data-based business decisions. It operates in Americas, EMEA and APAC, out of which maximum revenue from Americas.